Linezolid Krka

Linezolid, the active ingredient in Linezolid Krka, is an oxazolidinone presented as an injection solution for intravenous use. It treats complicated skin and skin structure infections, community‑acquired bacterial pneumonia, nosocomial pneumonia and infections caused by methicillin‑resistant Staphylococcus aureus (MRSA).

GNH USA supplies Linezolid Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is an oxazolidinone antibiotic indicated for several serious bacterial infections.

Complicated skin and skin structure infections: provides bacterial eradication and clinical cure in Gram‑positive infections, including MRSA. Community‑acquired bacterial pneumonia: targets susceptible Streptococcus pneumoniae and other pathogens to resolve pulmonary infection. Nosocomial pneumonia: effective against hospital‑acquired Gram‑positive organisms, aiding recovery. Methicillin‑resistant Staphylococcus aureus (MRSA) infections: offers activity against resistant strains to achieve microbiological clearance.

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: transient gastrointestinal upset. - Diarrhea: loose stools, usually self‑limited. - Headache: mild to moderate intensity. - Vomiting: occasional emesis. - Metallic taste: altered taste perception. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count requiring monitoring. - Peripheral neuropathy: sensory changes that may be irreversible. - Serotonin syndrome: risk when combined with serotonergic agents. - Lactic acidosis: metabolic disturbance in prolonged therapy. - Myelosuppression: bone‑marrow suppression affecting blood cells. - Optic neuropathy: visual disturbances that may be permanent.

Before initiating Linezolid therapy, consider the following safety measures.

Renal impairment: monitor renal function and adjust therapy as needed. Hepatic impairment: assess liver enzymes regularly. Concomitant serotonergic agents: avoid or closely monitor for serotonin syndrome. Long‑term therapy: perform periodic complete blood counts. Pregnancy and lactation: use only if benefits outweigh potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs): increased risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): potentiate serotonergic toxicity. - Tricyclic antidepressants: additive serotonin effects. - Rifampin: induces metabolism, reducing linezolid exposure. - Phenylpropanolamine: heightened serotonergic activity.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR, requiring coagulation monitoring. - Phenytoin: may lower linezolid concentrations. - Erythromycin: can raise linezolid levels, watch for toxicity. - NSAIDs: potential additive hematologic effects. - Digoxin: monitor serum levels for possible increase.